Strategic Partnerships Leverage KaloCyte’s BLUE KNIGHT collaboration with BARDA and JLABS, plus recent licensing with Chrysea Labs, to pursue co-development, manufacturing scale, and distribution opportunities with large biopharma and contract manufacturers seeking advanced oxygen carrier solutions.

Supply Chain Readiness Position ErythroMer as a shelf-stable, lyophilized red blood cell substitute for clinics, disaster response, military field use, and remote care settings where stored blood is scarce, enabling rapid adoption through OEM-like distribution channels and medical supply partners.

Bioderived Innovation Highlight ErythroMer’s immune-silent, antigen-free profile and long shelf life to target hospitals, blood banks, and trauma centers aiming to reduce cross-matching failures and supply vulnerabilities, with opportunities for regulatory support programs and pilot deployments.

Funding vs Commercialization Align sales efforts with the company’s strong federal and investor funding trajectory by offering strategic collaborations, sponsored research, and milestone-driven deals that de-risk early markets while accelerating regulatory-approved utility in emergencies.

Clinical Adoption Pathways Target institutions and networks focused on trauma, surgery, and disaster preparedness to pilot ErythroMer, leveraging UM Baltimore/CBOH affiliations to access key decision-makers, clinical evaluators, and potential reimbursement pathways for life-saving oxygen carriers.